NCT00632229View on ClinicalTrials.gov

Double Blinded, Placebo-Controlled Trial of Paliperidone Addition in SRI-Resistant Obsessive-Compulsive Disorder

PHASE2CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

September 30, 2013

Study Completion Date

September 30, 2013

Conditions
Obsessive-Compulsive Disorder
Interventions
DRUG

Paliperidone

Paliperidone medication taken daily ranging from 3-9mg/day depending on tolerability and efficacy.

DRUG

Placebo

Pill placebo taken daily ranging from 3-9mg/day depending on tolerability and efficacy.

Trial Locations (2)

33701

University of South Florida, St. Petersburg

46202

University Hospital Outpatient Center, Psychiatry, Indianapolis

All Listed Sponsors
collaborator

Indiana University

OTHER

collaborator

Ortho-McNeil Janssen Scientific Affairs, LLC

INDUSTRY

lead

University of South Florida

OTHER

NCT00632229 - Double Blinded, Placebo-Controlled Trial of Paliperidone Addition in SRI-Resistant Obsessive-Compulsive Disorder | Biotech Hunter | Biotech Hunter